AI Drug Discovery

3 articles tagged "AI Drug Discovery"

Eli Lilly Bets $2.75 Billion on AI Drug Discovery in Landmark Insilico Medicine Deal

US pharmaceutical giant Eli Lilly has signed a $2.75 billion licensing and collaboration agreement with Insilico Medicine, the Hong Kong-listed AI drug discovery company, in one of the largest AI-pharma deals ever recorded. The agreement validates the commercial maturity of AI-driven drug design after years of proof-of-concept claims.

D.O.T.S AI NewsroomMar 31, 20263 min read

Startups

Eli Lilly Signs $2.75 Billion Deal With AI Drug Developer Insilico Medicine

The pharmaceutical giant's landmark deal with the Hong Kong-listed AI biotech firm signals that big pharma is ready to write nine-figure checks for computational drug discovery — and that Insilico's AI-first pipeline has cleared a critical credibility threshold.

D.O.T.S AI NewsroomMar 30, 2026

Industry

Eli Lilly Forges Landmark $2.75 Billion Alliance with AI Drug Pioneer Insilico Medicine

Pharmaceutical titan Eli Lilly has entered a $2.75 billion agreement with Insilico Medicine, a pioneer in AI-driven drug discovery. This collaboration underscores a pivotal shift in pharmaceutical R&D, leveraging generative AI and reinforcement learning for novel therapeutic development.

D.O.T.S AI NewsroomMar 30, 2026